Home
AMRX
AMRX News

Latest Amneal Pharmaceuticals Inc. (AMRX) News on October 9, 2025

Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

Zacks

6 days ago

Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?

Zacks

7 days ago

Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?

Amneal Pharmaceuticals, Inc. (AMRX) Files BLA for XOLAIR® Biosimilar, Targets Multi-Billion-Dollar Market

Insider Monkey

8 days ago

Amneal Pharmaceuticals, Inc. (AMRX) Files BLA for XOLAIR® Biosimilar, Targets Multi-Billion-Dollar Market

Amneal to Report Third Quarter 2025 Results on October 30, 2025

GlobeNewswire

9 days ago

Amneal to Report Third Quarter 2025 Results on October 30, 2025

A Look at Amneal Pharmaceuticals's Valuation Following FDA Approval of Generic LUMIGAN

Simply Wall St.

15 days ago

A Look at Amneal Pharmaceuticals's Valuation Following FDA Approval of Generic LUMIGAN

MT Newswires

16 days ago

Amneal Pharmaceuticals Says FDA Approved Abbreviated NDA for Bimatoprost Ophthalmic Generic

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

GlobeNewswire

16 days ago

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

MT Newswires

a month ago

Amneal Pharmaceuticals Receives FDA Approval for Antipsychotic Medicine

Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension

GlobeNewswire

a month ago

Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension

MT Newswires

2 months ago

Amneal Pharmaceuticals Insider Sold Shares Worth $2,619,309, According to a Recent SEC Filing

MT Newswires

3 months ago

Amneal Pharmaceuticals Says Study Evaluating Biosimilar to Xolair For Chronic Hives Achieves Endpoints

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

GlobeNewswire

3 months ago

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

Generic Drugmakers Resist Trump’s Calls for More U.S. Manufacturing

The Wall Street Journal

4 months ago

Generic Drugmakers Resist Trump’s Calls for More U.S. Manufacturing

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

GlobeNewswire

4 months ago

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

Amneal to Participate at Upcoming Investor Conferences in June

GlobeNewswire

4 months ago

Amneal to Participate at Upcoming Investor Conferences in June

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

GlobeNewswire

5 months ago

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.

GlobeNewswire

5 months ago

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.

Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Call Highlights: Strong Growth and Strategic ...

GuruFocus.com

5 months ago

Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Call Highlights: Strong Growth and Strategic ...

Amneal Reports First Quarter 2025 Financial Results

Business Wire

5 months ago

Amneal Reports First Quarter 2025 Financial Results

Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Report Preview: What To Expect

GuruFocus.com

5 months ago

Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Report Preview: What To Expect

Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years

Simply Wall St.

6 months ago

Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years

Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month

Business Wire

6 months ago

Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month

Amneal to Report First Quarter 2025 Results on May 2, 2025

Business Wire

6 months ago

Amneal to Report First Quarter 2025 Results on May 2, 2025

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease

Business Wire

6 months ago

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

Business Wire

6 months ago

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

Business Wire

6 months ago

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

Amneal to Participate at Upcoming Investor Conference

Business Wire

7 months ago

Amneal to Participate at Upcoming Investor Conference

Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

Business Wire

7 months ago

Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

Amneal Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.

7 months ago

Amneal Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

Business Wire

7 months ago

Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

Amneal Pharmaceuticals Inc (AMRX) Q4 2024: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

7 months ago

Amneal Pharmaceuticals Inc (AMRX) Q4 2024: Everything You Need To Know Ahead Of Earnings

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

Business Wire

8 months ago

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

Although Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders have sold lately, they have the highest ownership with 51% stake

Simply Wall St.

8 months ago

Although Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders have sold lately, they have the highest ownership with 51% stake

7MM PD market to grow by $4.5bn between 2023 and 2033

Clinical Trials Arena

8 months ago

7MM PD market to grow by $4.5bn between 2023 and 2033

Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

Business Wire

8 months ago

Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

Kashiv Biosciences’ Phase I trial of KSHB002 injection meets primary endpoints

Clinical Trials Arena

8 months ago

Kashiv Biosciences’ Phase I trial of KSHB002 injection meets primary endpoints

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

Business Wire

9 months ago

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

Amneal to Participate at Upcoming Investor Conferences

Business Wire

10 months ago

Amneal to Participate at Upcoming Investor Conferences

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

Business Wire

a year ago

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

Amneal Pharmaceuticals Inc (AMRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

a year ago

Amneal Pharmaceuticals Inc (AMRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Amneal Reports Third Quarter 2024 Financial Results

Business Wire

a year ago

Amneal Reports Third Quarter 2024 Financial Results

Earnings To Watch: Amneal Pharmaceuticals Inc (AMRX) Reports Q3 2024 Result

GuruFocus.com

a year ago

Earnings To Watch: Amneal Pharmaceuticals Inc (AMRX) Reports Q3 2024 Result

Amneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211%

Simply Wall St.

a year ago

Amneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211%

Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets

Business Wire

a year ago

Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets

Amneal Pharmaceuticals Inc (AMRX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

a year ago

Amneal Pharmaceuticals Inc (AMRX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Amneal to Report Third Quarter 2024 Results on November 8, 2024

Business Wire

a year ago

Amneal to Report Third Quarter 2024 Results on November 8, 2024

Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases

Business Wire

a year ago

Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases

Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease

Business Wire

a year ago

Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

Business Wire

a year ago

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Business Wire

a year ago

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Insider Sale at Amneal Pharmaceuticals Inc (AMRX): Executive Vice President Nikita Shah Sells ...

GuruFocus.com

a year ago

Insider Sale at Amneal Pharmaceuticals Inc (AMRX): Executive Vice President Nikita Shah Sells ...

Amneal Pharmaceuticals Second Quarter 2024 Earnings: EPS: US$0.019 (vs US$0.078 in 2Q 2023)

Simply Wall St.

a year ago

Amneal Pharmaceuticals Second Quarter 2024 Earnings: EPS: US$0.019 (vs US$0.078 in 2Q 2023)

Amneal Reports Second Quarter 2024 Financial Results

Business Wire

a year ago

Amneal Reports Second Quarter 2024 Financial Results

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Business Wire

a year ago

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

Business Wire

a year ago

Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

In spite of recent selling, insiders still control 53% of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Simply Wall St.

a year ago

In spite of recent selling, insiders still control 53% of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Amneal to Report Second Quarter 2024 Results on August 9, 2024

Business Wire

a year ago

Amneal to Report Second Quarter 2024 Results on August 9, 2024

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant

Business Wire

a year ago

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant

Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Business Wire

a year ago

Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Business Wire

a year ago

Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)

Amneal Releases 2023 Environmental, Social and Governance Report

Business Wire

a year ago

Amneal Releases 2023 Environmental, Social and Governance Report

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

GuruFocus.com

a year ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

Energy Global

a year ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

USA TODAY

a year ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Business Wire

a year ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Business Wire

a year ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

SEALSQ to Launch Two New Quantum Resistant Chips

GlobeNewswire

a year ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Reuters

a year ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

GlobeNewswire

a year ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies

Business Wire

a year ago

Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies

Amneal to Participate at Upcoming Investor Conference

Business Wire

a year ago

Amneal to Participate at Upcoming Investor Conference

Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California

Business Wire

a year ago

Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California

Insider Sale: Director Deborah Autor Sells 38,000 Shares of Amneal Pharmaceuticals Inc (AMRX)

GuruFocus.com

a year ago

Insider Sale: Director Deborah Autor Sells 38,000 Shares of Amneal Pharmaceuticals Inc (AMRX)

Amneal Pharmaceuticals First Quarter 2024 Earnings: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)

Simply Wall St.

a year ago

Amneal Pharmaceuticals First Quarter 2024 Earnings: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)

GuruFocus.com

a year ago

Amneal Pharmaceuticals Inc (AMRX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...

Amneal Reports First Quarter 2024 Financial Results

Business Wire

a year ago

Amneal Reports First Quarter 2024 Financial Results

Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Business Wire

a year ago

Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine

Business Wire

a year ago

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine

Amneal Pharmaceuticals (NASDAQ:AMRX) shareholders are still up 235% over 1 year despite pulling back 8.0% in the past week

Simply Wall St.

a year ago

Amneal Pharmaceuticals (NASDAQ:AMRX) shareholders are still up 235% over 1 year despite pulling back 8.0% in the past week

Amneal to Report First Quarter 2024 Results on May 3, 2024

Business Wire

a year ago

Amneal to Report First Quarter 2024 Results on May 3, 2024

Amneal to Ring the Nasdaq Closing Bell on April 2, 2024

Business Wire

2 years ago

Amneal to Ring the Nasdaq Closing Bell on April 2, 2024

Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension

Business Wire

2 years ago

Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension

Amneal Pharmaceuticals Inc (AMRX) Reports Mixed 2023 Financial Results

GuruFocus.com

2 years ago

Amneal Pharmaceuticals Inc (AMRX) Reports Mixed 2023 Financial Results

Amneal Reports Fourth Quarter and Full Year 2023 Financial Results

Business Wire

2 years ago

Amneal Reports Fourth Quarter and Full Year 2023 Financial Results

Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203

Business Wire

2 years ago

Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203

Insiders the biggest winners as Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) market cap rises to US$1.8b

Simply Wall St.

2 years ago

Insiders the biggest winners as Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) market cap rises to US$1.8b

Amneal to Participate at Upcoming Investor Conference

Business Wire

2 years ago

Amneal to Participate at Upcoming Investor Conference

Amneal Announces Complete Response Resubmission for IPX203 New Drug Application

GlobeNewswire

2 years ago

Amneal Announces Complete Response Resubmission for IPX203 New Drug Application

Compared to Estimates, Cimpress (CMPR) Q2 Earnings: A Look at Key Metrics

Zacks

2 years ago

Compared to Estimates, Cimpress (CMPR) Q2 Earnings: A Look at Key Metrics

Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024

Business Wire

2 years ago

Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024

Kodiak Gas Services Announces Pricing of $750 Million Senior Unsecured Notes Offering

PR Newswire

2 years ago

Kodiak Gas Services Announces Pricing of $750 Million Senior Unsecured Notes Offering

CMS Awards ICF $33 Million Digital Modernization Contract

PR Newswire

2 years ago

CMS Awards ICF $33 Million Digital Modernization Contract

Portable-Building Companies Strike $3 Billion Deal

The Wall Street Journal

2 years ago

Portable-Building Companies Strike $3 Billion Deal

Kodiak Gas Services Announces Launch of $750 Million Senior Unsecured Notes Offering

PR Newswire

2 years ago

Kodiak Gas Services Announces Launch of $750 Million Senior Unsecured Notes Offering

Kodiak Gas Services Announces Quarterly Dividend of $0.38 per Share of Common Stock

PR Newswire

2 years ago

Kodiak Gas Services Announces Quarterly Dividend of $0.38 per Share of Common Stock

What's in Store for Rockwell Automation (ROK) in Q1 Earnings?

Zacks

2 years ago

What's in Store for Rockwell Automation (ROK) in Q1 Earnings?

These 2 Transportation Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks

2 years ago

These 2 Transportation Stocks Could Beat Earnings: Why They Should Be on Your Radar

Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203

GlobeNewswire

2 years ago

Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203

First Merchants Bank Announces Plans to Expand in Detroit, Bringing Financial Services to Fitzgerald

GlobeNewswire

2 years ago

First Merchants Bank Announces Plans to Expand in Detroit, Bringing Financial Services to Fitzgerald

Is EverCommerce Inc. (NASDAQ:EVCM) Trading At A 21% Discount?

Simply Wall St.

2 years ago

Is EverCommerce Inc. (NASDAQ:EVCM) Trading At A 21% Discount?

Share on Social Networks: